Oruka Therapeutics, Inc. Cash and Restricted Cash
Oruka Therapeutics, Inc. (ORKA) had Cash and Restricted Cash of $268.47 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $268.47M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $49.52M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46.94M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $91.25M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $268.47M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $49.52M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $46.94M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $91.25M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $65.40M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $83.57M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $61.58M 10-Q · filed 2026-08-10 | |
| 2024-09-30 | $410.88M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $15.12M 10-Q · filed 2025-08-11 | $33.28M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $27.74M 10-Q · filed 2025-05-14 | $35.90M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $37.43M 10-Q · filed 2024-08-01 | |
| 2023-09-30 | $38.49M 10-Q · filed 2023-10-18 | |
| 2023-06-30 | $40.16M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $40.85M 10-Q · filed 2024-04-25 | |
| 2022-12-31 | $42.45M 10-Q · filed 2024-08-01 | |
| 2022-09-30 | $43.94M 10-Q · filed 2023-10-18 | |
| 2022-06-30 | $46.44M 10-Q · filed 2023-07-21 | |
| 2022-03-31 | $49.06M 10-Q · filed 2023-04-24 | |
| 2021-12-31 | $53.36M 10-K · filed 2024-02-01 | |
| 2021-09-30 | $58.31M 10-Q · filed 2022-10-28 | |
| 2021-06-30 | $63.20M 10-Q · filed 2022-08-02 | |
| 2021-03-31 | $66.93M 10-Q · filed 2022-05-02 | |
| 2020-12-31 | $49.07M 10-K · filed 2023-02-24 | |
| 2020-09-30 | $51.09M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $11.04M 10-Q · filed 2021-08-04 | |
| 2020-03-31 | $6.67M 10-Q · filed 2021-05-11 | |
| 2019-12-31 | $8.36M 10-K · filed 2022-03-14 | |
| 2019-09-30 | $9.64M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $9.97M 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $8.01M 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $6.61M 10-K · filed 2021-03-18 | |
| 2018-09-30 | $8.06M 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $8.70M 10-K · filed 2020-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |